Ron Squarer’s 20-year career in the pharmaceutical industry has included a range of commercial, development and leadership roles
The appointment reflects Array’s ambitions as a developer of targeted drugs for cancer and inflammatory disorders.
Squarer, 45, joins Array from Hospira, where he was Chief Commercial Officer after being Senior VP, Global Marketing and Corporate Development. He was previously Senior VP, Global Corporate and Business Development, at oncology specialist Mayne Pharma, acquired by Hospira in 2007.
Earlier, he held senior management positions at Pfizer and SmithKline Beecham (now GSK).
“I am delighted to join Array, a recognised leader in small molecule drug development,” commented Ron Squarer. “Array is an exceptional company with 10 Array-invented drugs in phase 2, as well as outstanding people, a strong cash position and uniquely productive discovery and development capabilities.”
Kyle Lefkoff, Executive Chairman of Array, said: “Ron’s appointment is the culmination of the Board’s comprehensive selection process to identify the best executive to lead Array to the registration and commercialisation of our oncology and inflammation portfolio.”